Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
Abstract Methotrexate (MTX) is a common first-line treatment for new-onset rheumatoid arthritis (RA). However, MTX is ineffective for 30–40% of patients and there is no way to know which patients might benefit. Here, we built statistical models based on serum lipid levels measured at two time-points...
Main Authors: | Mateusz Maciejewski, Caroline Sands, Nisha Nair, Stephanie Ling, Suzanne Verstappen, Kimme Hyrich, Anne Barton, Daniel Ziemek, Matthew R. Lewis, Darren Plant |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-86729-7 |
Similar Items
-
What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis‐Based Approaches to Its Prediction?
by: Helga Westerlind, et al.
Published: (2021-07-01) -
Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)
by: Jamie C. Sergeant, et al.
Published: (2018-07-01) -
Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
by: James OIiver, et al.
Published: (2021-03-01) -
Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
by: James Oliver, et al.
Published: (2021-05-01) -
Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate
by: Mansour Salesi, et al.
Published: (2012-01-01)